RATIONALE: Pulmonary arterial hypertension is characterized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling, and increased elastase activity. Synthetic elastase inhibitors reverse experimental pulmonary hypertension but cause hepatotoxicity in clinical studies. The endogenous elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to improve endothelial function and BMPR2 signaling, and to reverse severe experimental pulmonary hypertension or vascular pathology in the human disease was unknown. OBJECTIVES: To assess elafin-mediated regression of pulmonary vascular pathology in rats and in lung explants from patients with pulmonary hypertension. To determine if elafin amplifies BMPR2 signaling in pulmonary artery endothelial cells and to elucidate the underlying mechanism. METHODS: Rats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia (Sugen/hypoxia) as well as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediated reversibility of pulmonary vascular disease. Pulmonary arterial endothelial cells from patients and control subjects were used to determine the efficacy and mechanism of elafin-mediated BMPR2 signaling. MEASUREMENTS AND MAIN RESULTS: In Sugen/hypoxia rats, elafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ventricular systolic pressure and hypertrophy and pulmonary artery occlusive changes. Elafin improved endothelial function by increasing apelin, a BMPR2 target. Elafin induced apoptosis in human pulmonary arterial smooth muscle cells and decreased neointimal lesions in lung organ culture. In normal and patient pulmonary artery endothelial cells, elafin promoted angiogenesis by increasing pSMAD-dependent and -independent BMPR2 signaling. This was linked mechanistically to augmented interaction of BMPR2 with caveolin-1 via elafin-mediated stabilization of endothelial surface caveolin-1. CONCLUSIONS: Elafin reverses obliterative changes in pulmonary arteries via elastase inhibition and caveolin-1-dependent amplification of BMPR2 signaling.
RATIONALE: Pulmonary arterial hypertension is characterized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling, and increased elastase activity. Synthetic elastase inhibitors reverse experimental pulmonary hypertension but cause hepatotoxicity in clinical studies. The endogenous elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to improve endothelial function and BMPR2 signaling, and to reverse severe experimental pulmonary hypertension or vascular pathology in the human disease was unknown. OBJECTIVES: To assess elafin-mediated regression of pulmonary vascular pathology in rats and in lung explants from patients with pulmonary hypertension. To determine if elafin amplifies BMPR2 signaling in pulmonary artery endothelial cells and to elucidate the underlying mechanism. METHODS:Rats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia (Sugen/hypoxia) as well as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediated reversibility of pulmonary vascular disease. Pulmonary arterial endothelial cells from patients and control subjects were used to determine the efficacy and mechanism of elafin-mediated BMPR2 signaling. MEASUREMENTS AND MAIN RESULTS: In Sugen/hypoxiarats, elafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ventricular systolic pressure and hypertrophy and pulmonary artery occlusive changes. Elafin improved endothelial function by increasing apelin, a BMPR2 target. Elafin induced apoptosis in human pulmonary arterial smooth muscle cells and decreased neointimal lesions in lung organ culture. In normal and patient pulmonary artery endothelial cells, elafin promoted angiogenesis by increasing pSMAD-dependent and -independent BMPR2 signaling. This was linked mechanistically to augmented interaction of BMPR2 with caveolin-1 via elafin-mediated stabilization of endothelial surface caveolin-1. CONCLUSIONS:Elafin reverses obliterative changes in pulmonary arteries via elastase inhibition and caveolin-1-dependent amplification of BMPR2 signaling.
Authors: Suparna M Chandra; Hedi Razavi; Jongmin Kim; Rani Agrawal; Ramendra K Kundu; Vinicio de Jesus Perez; Roham T Zamanian; Thomas Quertermous; Hyung J Chun Journal: Arterioscler Thromb Vasc Biol Date: 2011-01-13 Impact factor: 8.311
Authors: Tero-Pekka Alastalo; Molong Li; Vinicio de Jesus Perez; David Pham; Hirofumi Sawada; Jordon K Wang; Minna Koskenvuo; Lingli Wang; Bruce A Freeman; Howard Y Chang; Marlene Rabinovitch Journal: J Clin Invest Date: 2011-08-08 Impact factor: 14.808
Authors: Ali Roghanian; Steven E Williams; Tara A Sheldrake; Tom I Brown; Karen Oberheim; Zhou Xing; Sarah E M Howie; Jean-Michel Sallenave Journal: Am J Respir Cell Mol Biol Date: 2006-01-19 Impact factor: 6.914
Authors: Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: Thomas Bertero; Katherine A Cottrill; Yu Lu; Christina M Haeger; Paul Dieffenbach; Sofia Annis; Andrew Hale; Balkrishen Bhat; Vivek Kaimal; Ying-Yi Zhang; Brian B Graham; Rahul Kumar; Rajan Saggar; Rajeev Saggar; W Dean Wallace; David J Ross; Stephen M Black; Sohrab Fratz; Jeffrey R Fineman; Sara O Vargas; Kathleen J Haley; Aaron B Waxman; B Nelson Chau; Laura E Fredenburgh; Stephen Y Chan Journal: Cell Rep Date: 2015-10-22 Impact factor: 9.423
Authors: Nancy F Tojais; Aiqin Cao; Ying-Ju Lai; Lingli Wang; Pin-I Chen; Miguel A Alejandre Alcazar; Vinicio A de Jesus Perez; Rachel K Hopper; Christopher J Rhodes; Matthew A Bill; Lynn Y Sakai; Marlene Rabinovitch Journal: Arterioscler Thromb Vasc Biol Date: 2017-06-15 Impact factor: 8.311
Authors: Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-06-22 Impact factor: 5.464
Authors: Christa Gaskill; Shennea Marriott; Sidd Pratap; Swapna Menon; Lora K Hedges; Joshua P Fessel; Jonathan A Kropski; DeWayne Ames; Lisa Wheeler; James E Loyd; Anna R Hemnes; Dennis R Roop; Dwight J Klemm; Eric D Austin; Susan M Majka Journal: Pulm Circ Date: 2016-12 Impact factor: 3.017